Compare DexCom, Inc. (DXCM) vs Global X Uranium ETF (URA) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

The Global X Uranium ETF (URA) is trading at $38.99, down 6.16% over 24 hours amid a bearish technical signal. The fund's technical indicators show moving averages are unanimously bearish while oscillators are neutral, with RSI levels suggesting potential oversold conditions. Recent news highlights URA's position at the intersection of AI-driven power demand and nuclear energy growth, though the ETF faces competition from more focused uranium mining funds.

URA's outlook is supported by structural tailwinds including AI data center electricity needs and government nuclear initiatives, but near-term performance faces headwinds from technical selling pressure and investor preference for pure-play uranium exposure. The fund's 0.52% expense ratio remains higher than energy sector alternatives, creating a valuation challenge relative to peers.